Lorenzo Zaffiri1, Alex Long2, Megan L Neely3, Wida S Cherikh4, Daniel C Chambers5, Laurie D Snyder6. 1. Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina. Electronic address: lorenzo.zaffiri@duke.edu. 2. Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina. 3. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina. 4. United Network for Organ Sharing, Richmond, Virginia. 5. School of Medicine, The University of Queensland, Brisbane, Australia. 6. Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication following lung transplant. We studied incidence and risk factors for PTLD in adult lung transplant recipients (LTRs) using the International Society for Heart and Lung Transplantation Registry. METHODS: The International Society for Heart and Lung Transplantation Registry was used to identify adult, first-time, single and bilateral LTRs with at least 1 year of follow-up between 2006 and 2016. Kaplan-Meier method was used to describe the timing and distribution of PTLD. Univariable and multivariable Cox proportional hazards regression models were used to examine clinical characteristics associated with PTLD. RESULTS: Of 19,309 LTRs in the analysis cohort, we identified 454 cases of PTLD. Cumulative incidence of PTLD was 1.1% (95% CI = 1.0%-1.3%) at 1 year and 4.1% (95% CI = 3.6%-4.6%) at 10 years. Of the PTLD cases, 47.4% occurred within the first year following lung transplantation. In the multivariable model, independent risk factors for PTLD included age, Epstein-Barr virus serostatus, restrictive lung diseases, and induction. Risk of PTLD during the first year after transplant increased with increasing age in patients between 45 and 62 years at time of transplantation; the inverse was true for ages <45 years or >62 years. Finally, receiving a donor organ with human leukocyte antigen types A1 and A24 was associated with an increased risk of PTLD, whereas the recipient human leukocyte antigen type DR11 was associated with a decreased risk. CONCLUSIONS: Our study indicates that PTLD is a relatively rare complication among adult LTRs. We identified clinical characteristics that are associated with an increased risk of PTLD.
BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication following lung transplant. We studied incidence and risk factors for PTLD in adult lung transplant recipients (LTRs) using the International Society for Heart and Lung Transplantation Registry. METHODS: The International Society for Heart and Lung Transplantation Registry was used to identify adult, first-time, single and bilateral LTRs with at least 1 year of follow-up between 2006 and 2016. Kaplan-Meier method was used to describe the timing and distribution of PTLD. Univariable and multivariable Cox proportional hazards regression models were used to examine clinical characteristics associated with PTLD. RESULTS: Of 19,309 LTRs in the analysis cohort, we identified 454 cases of PTLD. Cumulative incidence of PTLD was 1.1% (95% CI = 1.0%-1.3%) at 1 year and 4.1% (95% CI = 3.6%-4.6%) at 10 years. Of the PTLD cases, 47.4% occurred within the first year following lung transplantation. In the multivariable model, independent risk factors for PTLD included age, Epstein-Barr virus serostatus, restrictive lung diseases, and induction. Risk of PTLD during the first year after transplant increased with increasing age in patients between 45 and 62 years at time of transplantation; the inverse was true for ages <45 years or >62 years. Finally, receiving a donor organ with human leukocyte antigen types A1 and A24 was associated with an increased risk of PTLD, whereas the recipient human leukocyte antigen type DR11 was associated with a decreased risk. CONCLUSIONS: Our study indicates that PTLD is a relatively rare complication among adult LTRs. We identified clinical characteristics that are associated with an increased risk of PTLD.
Authors: Daniel C Chambers; Wida S Cherikh; Samuel B Goldfarb; Don Hayes; Anna Y Kucheryavaya; Alice E Toll; Kiran K Khush; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Josef Stehlik Journal: J Heart Lung Transplant Date: 2018-08-11 Impact factor: 10.247
Authors: Marion Subklewe; René Marquis; Sylvain Choquet; Veronique Leblond; Jeanne-Luce Garnier; Roland Hetzer; Lode J Swinnen; Stephan Oertel; Matthias Papp-Vary; Eva Gonzalez-Barca; Bouke G Hepkema; Constanze Schoenemann; Juergen May; Antonio Pezzutto; Hanno Riess Journal: Transplantation Date: 2006-10-27 Impact factor: 4.939
Authors: R Reshef; M R Luskin; M Kamoun; S Vardhanabhuti; J E Tomaszewski; E A Stadtmauer; D L Porter; D F Heitjan; De E Tsai Journal: Am J Transplant Date: 2011-03-14 Impact factor: 8.086
Authors: Erin M Lowery; William Adams; Shellee A Grim; Nina M Clark; Leah Edwards; Jennifer E Layden Journal: J Cyst Fibros Date: 2017-04-27 Impact factor: 5.482
Authors: Anthea C Peters; Michael S Akinwumi; Carlos Cervera; Curtis Mabilangan; Sunita Ghosh; Raymond Lai; Marco Iafolla; Karen Doucette; Jutta K Preiksaitis Journal: Transplantation Date: 2018-09 Impact factor: 4.939
Authors: Maja Ølholm Vase; Eva Futtrup Maksten; Charlotte Strandhave; Esben Søndergaard; Knud Bendix; Stephen Hamilton-Dutoit; Claus Andersen; Michael Boe Møller; Søren Schwartz Sørensen; Jan Kampmann; Hans Eiskjær; Martin Iversen; Ilse Duus Weinreich; Bjarne Møller; Bente Jespersen; Francesco d'Amore Journal: Transplant Direct Date: 2015-08-11
Authors: Lorenzo Zaffiri; Courtney Frankel; Erika J Bush; Megan L Neely; Elizabeth N Pavlisko; Irina L Mokrova; Micah A Luftig; Scott M Palmer Journal: J Med Virol Date: 2021-03-25 Impact factor: 20.693